“The present problem has uncovered some structural weaknesses within the EU’s medicines offer chain and also a higher dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides stated. She advisable that supply chain problems be tackled in an EU pharmaceutical approach predict